General Information of Drug (ID: DMP5A4T)

Drug Name
Trilaciclib Drug Info
Synonyms
G1T28; 1374743-00-6; Trilaciclib [USAN]; G1T28(Trilaciclib); GTPL9626; CHEMBL3894860; SCHEMBL10082028; BDBM253928; US9464092, T; HY-101467; CS-0021431; 2'-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro(cyclohexane-1,9'-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one; Spiro(cyclohexane-1,9'(6'H)-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one, 7',8'-dihydro-2'-((5-(4-methyl-1-piperazinyl)-2-pyridinyl)amino)-; 2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[7,8-dihydropyra
Indication
Disease Entry ICD 11 Status REF
Small-cell lung cancer 2C25.Y Approved [1]
Triple negative breast cancer 2C60-2C65 Phase 2 [2]
Cross-matching ID
PubChem CID
68029831
CAS Number
CAS 1374743-00-6
TTD Drug ID
DMP5A4T

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Apremilast DMTWS9E Psoriasis vulgaris EA90 Approved [3]
LY2835219 DM93VBZ Breast cancer 2C60-2C65 Approved [4]
Palbociclib DMD7L94 Breast cancer 2C60-2C65 Approved [5]
Ribociclib Succinate DM9CIUW Breast cancer 2C60-2C65 Approved [6]
LEE011 DMMX75K Breast cancer 2C60-2C65 Phase 3 [7]
Ro 31-7453 DM83QCL Solid tumour/cancer 2A00-2F9Z Phase 2 [8]
P276-00 DM9DJL2 Mantle cell lymphoma 2A85.5 Phase 2 [9]
P-276 DMMJUHD Breast cancer 2C60-2C65 Phase 2 [10]
G1T38 DMQO2IT Breast cancer 2C60-2C65 Phase 2 [2]
GLR2007 DM7DWLY Glioblastoma of brain 2A00.00 Phase 1/2 [11]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Apremilast DMTWS9E Psoriasis vulgaris EA90 Approved [3]
LY2835219 DM93VBZ Breast cancer 2C60-2C65 Approved [4]
Palbociclib DMD7L94 Breast cancer 2C60-2C65 Approved [5]
Ribociclib Succinate DM9CIUW Breast cancer 2C60-2C65 Approved [6]
LEE011 DMMX75K Breast cancer 2C60-2C65 Phase 3 [7]
G1T38 DMQO2IT Breast cancer 2C60-2C65 Phase 2 [2]
GLR2007 DM7DWLY Glioblastoma of brain 2A00.00 Phase 1/2 [11]
FCN-437 DMQ8VUW Breast cancer 2C60-2C65 Phase 1/2 [12]
NUV-422 DMQJQNT Malignant glioma 2A00.0 Phase 1/2 [13]
FN-1501 DM7BMD6 Solid tumour/cancer 2A00-2F9Z Phase 1 [14]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cyclin-dependent kinase 4 (CDK4) TT0PG8F CDK4_HUMAN Inhibitor [1]
Cyclin-dependent kinase 6 (CDK6) TTO0FDJ CDK6_HUMAN Inhibitor [1]

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Agreement signed with Prostagenics to develop prostate cancer treatment. Innovate Oncology, Inc. 2005.
4 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2017
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7 Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013 Nov 15;19(22):6173-82.
8 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
9 Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
10 Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011:483154.
11 Clinical pipeline report, company report or official report of Gan & Lee Pharmaceuticals.
12 Clinical pipeline report, company report or official report of Fochon Pharmaceuticals.
13 ClinicalTrials.gov (NCT04541225) Phase 1/2 Dose Escalation, Safety, Pharmacokinetics, and Efficacy Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors. U.S.National Institutes of Health.
14 Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. J Med Chem. 2018 Feb 22;61(4):1499-1518.